Highlights•The contribution of pregnancy hypertension to maternal mortality is almost
certainly under-estimated.•Solutions relate to both societal and medical interventions.• …

Pre-eclampsia remains the second leading direct cause of maternal death,> 99% of which
occurs in less developed countries. Over 90 percent of the observed reduction in pre …

АННОТАЦИЯ Клинические рекомендации" Гипертензивные расстройства во время
беременности, в родах и послеродовом периоде. Преэклампсия. Эклампсия" …

Background Hypertensive disorders account for 14% of global maternal deaths. Magnesium
sulphate (MgSO4) is recommended for prevention and treatment of pre …

Background and objectives Hypertensive disorders of pregnancy (HDPs) remain one of the
leading causes of maternal mortality globally, especially in Low-and middle-income …

Introduction The optimal dosing regimen of magnesium sulfate for treating preeclampsia and
eclampsia is unclear. Evidence from the Cochrane review of randomized controlled trials …

Objective Eclampsia remains a public health issue, especially in low-resource countries
worldwide. Midwives are the backbone of the pregnancy and delivery process. Midwives …

Optimum dose, route and duration of use of prophylactic magnesium sulphate in women
with severe pre-eclampsia is still controversial. We compared the efficacy and safety of 'low …

Objectives This meta-analysis aimed to compare the benefits and risks of shortened
magnesium sulfate with traditional 24 h for severe postpartum preeclampsia. Methods We …

Background Early case detection, treatment, and timely referral for better services can
significantly reduce the negative outcomes of preeclampsia and eclampsia. However …